Research study Program year 2025 Source: CMS Open Payments

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-To-Severe Atopic Dermatitis

ClinicalTrials.gov NCT05559359

Research payments

$1,423,050

108 payments

Through program year 2025, $1,423,050 in research payments was reported against A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-To-Severe Atopic Dermatitis, across 108 payments, paid by Eli Lilly and Company.

Paid by: Eli Lilly and Company
ClinicalTrials.gov: NCT05559359

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$380,203	32
2024	Research	$992,444	48
2023	Research	$12,500	1
2022	Research	$37,903	27

Breakdown

Who paid Research payments · program years 2022–2025

Eli Lilly and Company $1,423,050 108 payments

Who received the money Research payments · program years 2022–2025

Dermatology Research Associates INC Organisation paid for research $210,033 5 payments
Texas Dermatology And Laser Specialists Organisation paid for research $163,398 5 payments
Osman Dermatology Organisation paid for research $144,564 5 payments
Medical University of South Carolina Organisation paid for research $110,574 4 payments
Allergy And Asthma Specialists Psc Organisation paid for research $109,239 5 payments
Medical College Of Wisconsin INC Organisation paid for research $92,467 5 payments
Clinical Research Ctr Of Alabama, LLC Organisation paid for research $69,693 3 payments
Treasure Valley Medical Research Organisation paid for research $61,155 4 payments
Arkansas Research Trials LLC Organisation paid for research $58,742 5 payments
Solutions Through Advanced Research Organisation paid for research $44,128 3 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.

Cite this record

“A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-To-Severe Atopic Dermatitis”, Who Paid My Doc, citing CMS Open Payments, program year 2025. https://www.whopaidmydoc.com/research-studies/a-randomized-double-blind-placebo-controlled-phase-3-study-to-assess-the-efficacy-safety-and-pharmacokinetics-of-lebrikizumab-compared-to-placebo-in-participants-6-months-to-18-years-of-age-with-moderate-to-severe-atopic-dermatitis-59252764

Figures here may be reproduced with attribution and a link — see for journalists and researchers.